Amrize vs CRH Public
AMRZ and CRH side by side, both in materials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRZ and CRH compare
CRH Public is the larger company, worth 2.7 times as much as Amrize ($60.3B against $22.6B).
On earnings, CRH Public is cheaper: it trades at 17.0× trailing earnings, against 18.2× for Amrize.
CRH Public grew revenue faster over the last twelve months (5.6% versus 3.5% for Amrize).
Amrize keeps more of each dollar of sales as profit, with a net margin of 10.2% compared with 9.2% at CRH Public.
Both pay dividends: Amrize yields 1.6% and CRH Public 1.3%.
CRH Public scores higher on the StockData Score (15 against 10 for Amrize), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRZ | CRH |
|---|---|---|
| Size and price | ||
| Market cap | $22.6B | $60.3B |
| Share price | $41.38 | $90.62 |
| Change, 1 year | −21.7% | −24.4% |
| Change, 5 years | – | 83.1% |
| Beta (5Y) | 0.73 | 1.11 |
| Employees | 19K | 83K |
| StockData Score | ||
| Total score | 10 | 15 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 3 | 3 |
| Dividend score | 1 | 2 (better) |
| Valuation | ||
| P/E | 18.2× | 17.0× (better) |
| P/S | 1.8× | 1.5× (better) |
| P/B | 1.8× (better) | 2.4× |
| EV/EBITDA | 10.2× | 10.0× (better) |
| P/FCF | 21.0× (better) | 23.7× |
| PEG | – | 6.70 |
| FCF yield | 4.8% (better) | 4.2% |
| Fair value | $47.20 | $101.39 |
| Margin of safety | 12.3% (better) | 10.6% |
| Growth | ||
| Revenue growth (TTM) | 3.5% | 5.6% (better) |
| Revenue growth, 5Y average | – | 7.7% |
| Net income growth (TTM) | 8.3% (better) | 4.3% |
| EPS growth (TTM) | 8.6% (better) | 6.0% |
| EPS growth, 5Y average | – | 31.2% |
| Profitability | ||
| Gross margin | 24.8% | 36.2% (better) |
| Operating margin | 15.5% (better) | 13.7% |
| Net margin | 10.2% (better) | 9.2% |
| FCF margin | 8.8% (better) | 6.5% |
| Return on equity | 9.8% | 14.8% (better) |
| Return on invested capital | 9.7% | 10.0% (better) |
| Financial health | ||
| Debt / equity | 0.46 (better) | 0.79 |
| Net debt / EBITDA | 2.00 | 1.91 (better) |
| Interest coverage | 5.3× | 6.3× (better) |
| Current ratio | 1.07 | 1.46 (better) |
| Altman Z-score | 2.03 | 2.68 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.6% (better) | 1.3% |
| Years of dividend growth | – | 4 |
| Buyback yield | – | 1.6% |
| Shareholder yield | 1.6% | 2.9% (better) |
| Ownership | ||
| Held by institutions | 47.1% | 84.7% |
| Held by insiders | 7.4% | 0.15% |
| Insider net buying, 12 months | $10.2M (better) | $445K |
| Superinvestors holding | 3 | 5 (better) |
| Short interest, % of float | 2.2% | 1.9% |
Go deeper
- AMRZ stock overview
- AMRZ income statement
- AMRZ valuation and score
- CRH stock overview
- CRH income statement
- CRH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.